Apoptosis is a programmed cellular process that occurs in pathological and physiological pathways and it is one of the most studied topics in cell biology. To understand the underlying mechanism of apoptosis plays an important role in the molecular pathogenesis of many diseases including cancers. Chronic myeloid leukemia (CML) is a clonal myeloproliferative malignancy arising from the neoplastic transformation of the hematopoietic stem cell. Here, we used a Bcr-Abl-independent, imatinib-resistant K562 subpopulation (K562-IR) generated and characterized earlier in our laboratory. We showed that the proteins Bcl-2, Bim, RIP, p-MAPK(Erk1/Erk2) and NF-kappa B which plays critical roles in cell death pathways are downregulated, Lamin A/C protein...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
B-cell chronic lymphocytic leukemia (B-CLL), characterized by an accumulation of monclonal B cells, ...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
Apoptosis is a programmed cellular process that occurs in pathological and physiological pathways an...
Bcr-Abl is a constitutively active tyrosine kinase involved in the development and progression of ch...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
Bcr-Abl is a constitutively active tyrosine kinase involved in the development and progression of ch...
PubMed ID: 29808796Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the...
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromo...
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromo...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
The disturbance of apoptosis molecular signaling pathways is involved in carcinogenesis. BCL2 family...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
B-cell chronic lymphocytic leukemia (B-CLL), characterized by an accumulation of monclonal B cells, ...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
Apoptosis is a programmed cellular process that occurs in pathological and physiological pathways an...
Bcr-Abl is a constitutively active tyrosine kinase involved in the development and progression of ch...
The kinase activity of BCR-ABL1 is central to chronic myeloid leukaemia (CML) pathology. Clinical tr...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
The resistance to apoptotic death has a key role in the illegitimate enlargement of chronic myeloid ...
Bcr-Abl is a constitutively active tyrosine kinase involved in the development and progression of ch...
PubMed ID: 29808796Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by the...
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromo...
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromo...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
The disturbance of apoptosis molecular signaling pathways is involved in carcinogenesis. BCL2 family...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...
B-cell chronic lymphocytic leukemia (B-CLL), characterized by an accumulation of monclonal B cells, ...
Imatinib mesylate is a potent inhibitor of Bcr-Abl tyrosine kinase, an oncoprotein that plays a key ...